Candida vulvovaginitis

Background

Labeled vulva, showing external and internal views.
Pelvic anatomy including organs of the female reproductive system.
  • Local fungal infection caused by the Candida genus (most commonly Candida albicans)
  • Most commonly seen in females in high estrogen states: pregnancy, oral contraceptive use, obesity, diabetes mellitus
  • Not considered an STI although it can be transmitted by sexual intercourse
  • May occur in premarnarcheal girls (rare)
  • Can occur as a result of antibiotic use

Types[1]

  • Uncomplicated (must have all)
    • Sporadic infection
    • Mild-moderate symptoms
    • Due to Candida albicans (suspected or proven)
    • Immunocompetent
  • Complicated (presence of ANY of the following)
    • Any species other than C. albicans
    • Recurrent infection (defined as ≥4 episodes per year)
    • Severe symptoms or findings
    • Poorly controlled diabetes, immunocompromising conditions (such as HIV), debilitation, or immunosuppressive therapy (e.g., corticosteroids)

Clinical Features

Candida vaginitis

Differential Diagnosis

Vulvovaginitis

Evaluation

KOH test on a vaginal wet mount, showing slings of pseudohyphae of Candida albicans surrounded by round vaginal epithelial cells.

Work-up

  • Urine pregnancy
  • Wet mount
  • Consider blood glucose (if recurrent, to check for occult DM)
  • Consider tests for STIs

Diagnosis

  • Cotton cheese curd-like non-odorous vaginal discharge on pelvic exam
  • Vaginal pH < 4.5
  • Vaginal wet mount
    • Hyphae and yeast buds
    • Candida does not cause WBCs on wet mount → if present, consider co-infection with other vaginitides or STI

Management

  • Do not treat if asymptomatic
  • Sexual partners should not be treated unless the patient has frequent recurrences
  • Does not need a test of cure

Antifungals

Uncomplicated

There is little resistance to azole medications; treatment often dictated by patient preference.

  • Fluconazole 150mg PO once[3]
  • Intravaginal therapy
    • Clotrimazole 1% cream applied vaginally for 7 days OR 2% applied vaginally for 3 days
    • Miconazole 2% cream applied vaginally for 7 days OR 4% cream x 3 days
    • Butoconazole 2% applied vaginally x 3 days
    • Tioconazole 6.5% applied vaginally x 1

Complicated

Severe or immunosuppressed

Non-albicans species

  • For example, C. glabrata, C. krusei and other atypical Candida spp.
  • Boric acid vaginal suppository intravaginal qday x ≥14 days
    • Can be fatal if taken orally
  • If empirically treated and later is found to have non-albicans Candida spp., no change in therapy is needed if patient is improving (otherwise switch to boric acid.

Recurrent (≥ 4 infections in a year)

  • Treat as for uncomplicated (see above)
  • Once therapy completed, prescribe long-term treatment
    • Fluconazole 150mg PO qweek x 6 months OR
    • Intravaginal medication, such as clotrimazole 500mg PV qweek or 200mg PV twice a week

Pregnant Patients

  • Intravaginal clotrimazole or miconazole are the only recommended treatments
  • Duration is 7 days
  • PO fluconazole associated with congenital malformations and spontaneous abortions[4]

Disposition

  • Outpatient
    • Refer all "complicated" cases to gynecology

See Also

References

  1. ↑ Adapted from ACOG practice bulletin
  2. ↑ Kauffmann CA. Overview of Candida Infections. UptoDate. 2016.
  3. ↑ Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.
  4. ↑ Molgaard-Nielsen D et al. Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. JAMA. 2016;315(1):58-67.